Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of cetuximab plus TPF neoadjuvant therapy followed by cisplatin chemoradiotherapy plus cetuximab in locoregional esophageal cancer
2006-001880-42Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jun 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, docetaxel, cisplatin and fluorouracil in esophageal cancer, sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoints: Clinical complete response rate and Pathological complete response rate. Started Jun 2006; status: completed.
02
Drugs
cetuximabdocetaxelcisplatinfluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on 2006-001880-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001880-42.